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Abstract
Background: Analysis of DNA copy number alterations and gene expression changes in human samples have
been used to find potential target genes in complex diseases. Recent studies have combined these two types of
data using different strategies, but focusing on finding gene-based relationships. However, it has been proposed
that these data can be used to identify key genomic regions, which may enclose causal genes under the
assumption that disease-associated gene expression changes are caused by genomic alterations.
Results: Following this proposal, we undertake a new integrative analysis of genome-wide expression and copy
number datasets. The analysis is based on the combined location of both types of signals along the genome. Our
approach takes into account the genomic location in the copy number (CN) analysis and also in the gene
expression (GE) analysis. To achieve this we apply a segmentation algorithm to both types of data using paired
samples. Then, we perform a correlation analysis and a frequency analysis of the gene loci in the segmented CN
regions and the segmented GE regions; selecting in both cases the statistically significant loci. In this way, we find
CN alterations that show strong correspondence with GE changes. We applied our method to a human dataset of
64 Glioblastoma Multiforme samples finding key loci and hotspots that correspond to major alterations previously
described for this type of tumors.
Conclusions: Identification of key altered genomic loci constitutes a first step to find the genes that drive the
alteration in a malignant state. These driver genes can be found in regions that show high correlation in copy
number alterations and expression changes.
Background
Acquisition of somatic genetic alterations plays an
important role in the development of cancer. Several sys-
tematic efforts have addressed the study of genetic altera-
tions to characterize human cancers [1,2], including:
copy-number alterations (CNAs), translocations, inser-
tions or single-nucleotide polymorphisms (SNPs). Most
of these approaches are focused on finding frequent
alterations, which occur in a high number of cases.
According to the selective pressure theory, a genomic
alteration that confers an advantage to a malignant state
is likely to be found in more tumors than expected by
chance [3]. However, most methods that look for recur-
rent aberrations using copy number information find
many regions, containing many genes [4,5]. Therefore, to
identify recurrently altered genomic regions -biologically
relevant- it is necessary to integrate gene and genome
information, as proposed by Akavia et al. [3]. Several
reports have recently shown that integrative strategies can
be very useful to identify driver genes, considering the
hypothesis that disease-associated gene expression changes
are frequently induced by genomic alterations [3,6-10].
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Most of these reports are focused on finding gene-based
relationships.
Built on these hypotheses -that relate transcriptomic and
genomic alterations-, we propose a new integrative
method based on the location of both types of signals
along the genome. Our method takes into account the
genomic loci, both in the copy number (CN) analysis and
also in the gene expression (GE) analysis, and applies the
segmentation step proposed by Ortiz-Estevez et al. [11].
These authors designed a method for robust comparison
between CN and GE using paired samples. Such approach
is based on a search for correlation between segmented
CN regions and segmented GE regions to find the most
significant simultaneous alterations. We follow this
approach introducing two new steps to asses the matching
between CN and GE loci: (i) first, a signal correlation ana-
lysis; (ii) second, an alteration frequency analysis. Using
these analyses we propose a set of significantly altered
genomic regions in the studied pathological state. In order
to show the performance and demonstrate the value of
our method, we use a dataset of 64 Glioblastoma Multi-
forme (GBM) samples with paired measurements of GE
and CN (taken from [7,8]).
Results and discussion
The method is designed for combined analysis of datasets
from two types of genome-wide arrays: DNA genomic
microarrays and RNA expression microarrays. These
arrays provide copy number and expression quantitative
data, respectively. The analysis places both types of signals
along the genome, taking into account the gene loci for
the CN data and the GE data. The rationale of the method
is to search for copy number alterations with a major
influence in the expression levels of the genes encoded. As
a distinctive element from other integrative approaches we
do not consider only SNPs or genes individually. We take
into account the gene loci following the strategy described
in [11], that is based on the application of the same
smoothing and segmentation algorithm to CN and GE in
order to establish comparable regions. Once we get the
smoothed segments, we perform two independent analyses
for each gene loci: a signal correlation analysis and an
alteration frequency analysis. (The workflow described in
Materials and Methods, presented in last figure, illustrates
the procedure of the method including these two indepen-
dent analyses).
Analysis of correlation between gene expression and
copy number levels
The method matches the CN and GE segmented signals
within each chromosomal region -i.e., the log2 ratio sig-
nals of the corresponding segments- and selects the gene
loci that show a significant correlation. These loci can be
considered candidate hotspots. In Figure 1 we present the
results of this analysis done for the GBM dataset, marking
in purple the number of gene loci with Pearson Correla-
tion Coefficient r ≥ 0.60 (that corresponds to a Bonfer-
roni-adjusted p-value < 0.005). Such cutoff (r ≥ 0.60)
includes around 55 % of the human gene loci, providing a
good coverage with a significant p-value. Setting more
stringent cutoffs reduces the coverage too much: r ≥ 0.70
includes only ~26 % of the gene loci; r ≥ 0.80 includes
only ~6 %.
The number of probes in the SNP arrays -used to calcu-
late the segmented signals for CN- is large and uniform
along the genome. However, in the expression arrays
some genomic regions do not have enough allocated gene
loci and the number of probes is sparse. This fact is a pro-
blem when a GE segment includes outliers (i.e. gene locus
which have expression levels very different from the mean
of their neighbours). To solve this problem, we look for
statistically significant outliers within the GE segments
-which were at least in 1/3 of the samples- and we recalcu-
late the signal correlation between their unsegmented GE
and the corresponding CN segments. In this way, we find
a new set of gene loci with correlation r ≥ 0.60, which is
added to the initial set of candidate hotspots identified.
This step of the procedure is important to recover some
gene loci with quite significant correlation (e.g. EGFR or
SEC61G), which were missed in the first step due to the
described problem.
Analysis of frequencies for the categorical states Up-Gain
and Down-Loss
The method also proposes to find the genomic regions
that present a significant GE and CN alteration in the
same direction. To assess this, we included a second selec-
tive step based on stratification of the segmented data.
The genomic regions are stratified in several categories:
up-regulation (U), down-regulation (D) or no-change (N)
for expression; and gain (G), loss (L) or no-change (N) for
copy number. This approach allows a discretization of the
genomic regions into 9 different categories as shown in
Figure 2 (inserted table): U-G, N-G, D-G, U-N, N-N,
D-N, U-L, N-L, D-L. Figure 2 also presents the empirical
cumulative distributions for these 9 categories of the GBM
samples per gene loci, counting the frequency of samples
for all the gene loci in each category. As expected, the
distributions show that the “no change” (i.e. N-N, neutral-
neutral) is the most frequent state. The analysis of distri-
butions also finds some regions that show a clear corre-
spondence between GE and CN alterations: i.e. the
scenario where GE up-regulation is observed co-located
with a CN gain (U-G category) and the scenario where GE
down-regulation is co-located with a CN loss (D-L cate-
gory). Our interest focuses on these regions, since they are
the ones altered in the same way in both types of data.
The analysis of the empirical frequency distributions for
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the U-G and D-L categories allows identifying the fre-
quency cutoffs that correspond to the 10% upper quan-
tiles. These cutoffs were: 13 samples for U-G and 11
samples for D-L (out of 64 in GBM dataset). The set up of
these thresholds identifies those genomic regions that are
the most frequently assigned to such altered categories
(U-G and D-L) in the studied dataset.
Genome-wide identification of hotspots: candidate key
genomic regions
Our method identifies candidate key regions that show
high correlation between CN and GE and that are fre-
quently altered in the same direction, in both types of
signals. The overlapping between the regions with the
most significant correlation and the ones with the highest
frequencies of simultaneous alteration (CN and GE) along
the genome, will constitute hotspots where putative driver
genes are likely to be encoded.
Figure 3 presents the combined view of GE and CN
alterations on the complete genome obtained for the
GBM dataset. The graph shows the alteration frequency,
either in CN or in GE independently, along all the genome
(22 human chromosomes). The dark colors correspond to
GE up-regulated regions (red) or down-regulated regions
(green), and the light colors -placed on top- correspond to
CN gains (pale red) and losses (pale green). These results
Figure 1 Density distribution of the correlation coefficients between GE and CN for the GBM dataset. Purple represents the number of
gene loci that present significant correlation (r ≥ 0.60) between gene expression and copy number signals, counted considering all the samples.
Blue are the rest, not considered significant.
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show that the method finds the alterations previously
described for CN in GBM cancer [12,13]. In fact, the most
frequent alterations in glioblastoma are the gain of chro-
mosome 7 and the loss of chromosome 10. Our analysis
finds such alterations in CN, and also finds their correla-
tion with GE up-regulation for chromosome 7 and with
GE down-regulation for chromosome 10. Figure 4 pre-
sents a detailed view of the alterations that occur in chro-
mosome 7. It includes a profile of the regions with
significant correlation (purple dots along the chromo-
some) and a profile of the frequency of U-G regions (pale
red). They cover nearly the complete chromosome. A
figure with the representation for all the 22 human chro-
mosomes for the GBM samples is included as Additional
File 3.
Key genomic regions found for the 64 paired GBM cancer
samples
As shown in Figure 3, the method presented in this work
allows the identification of relevant altered genomic
regions suffering significant changes in most of the GBM
samples. The results also show that many of the detected
CN alterations and GE changes overlap along the genome.
These regions can be proposed as relevant “hotspots”. In
Table 1 and Table 2 we present a detailed description of
the common genomic regions found in GBM; indicating
the correlation and frequency of the U-G regions (Table 1,
which includes 19 regions), and the D-L regions (Table 2,
which includes 24 regions). The tables include the correla-
tion between GE and CN for each region (as average cor-
relation for all the gene loci); and the percentage of
samples -frequency- in each region, counting only the
samples where simultaneous GE and CN alterations
occur: either up gene expression and gain in copy number
(U-G) or down gene expression and loss in copy number
(D-L). The regions detected are in the chromosomes that
suffer the most significant changes in GBM samples: U-G,
chr 7 and chr 20; D-L chr 10, chr 13, chr 14 and chr 22.
The tables also include the genes enclosed in these
regions. The most remarkable changes correspond to a
Figure 2 Observed frequency distributions of the 9 categorical states for the GBM dataset: U-G, N-G, D-G, U-N, N-N, D-N, U-L, N-L, D-L.
Boxplots corresponding to the distributions of number of samples assigned to each category for all the gene loci. Insert: Contingency table
showing the 9 possible categories for the gene expression and copy number. The total number of GBM samples analysed was 64.
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large part of chr 7 (U-G) and to a large part of chr 10
(D-L). Two important genes are precisely located in these
chromosomes: EGFR (in chr 7) usually up-regulated and
PTEN (in chr 10) usually down-regulated [12,13]. PTEN is
not found in our analysis, but it has been reported an
absence of PTEN alterations in more than half of de novo
glioblastomas and more than 90 % of glioblastomas
developed from a pre-existing lower grade gliomas [14],
which has been linked to the presence of additional tumor
suppressor genes on chr 10, such as LGI1 [15] and MXI1
[16]. We found these two genes in regions 8 and 10 of the
D-L list (Table 2), and we observed a very variable profile
of PTEN in the GBM samples. These facts may indicate
that PTEN is not the best genomic marker for this altered
Figure 3 Combined view of GE and CN alterations obtained for the GBM dataset. The regions for all the human chromosomes (chr) that
are altered either in CN or in GE are presented along the whole genome keeping the proportional size of the chromosomes. The graph shows
the frequency of such alterations in the GBM samples. The colors correspond to GE up-regulated regions (in red) or down-regulated regions (in
green), and -plotted on top- the CN gains (in pale red) or the CN losses (in pale green). Blue lines mark the regions that change in more than
25% of the GBM patients. The chromosomes with most significant changes (that present large regions included in the categories U-G or D-L)
are labeled: U-G chr 7, chr 19, chr 20; D-L chr 10, chr 13, chr 22.
Figure 4 Detailed view of chromosome 7 showing the CN and GE correlation and the U-G category frequency for the GBM dataset.
The genomic regions for chromosome 7 are represented in X-axis. Blue and purple dots show the correlation coefficients between CN and GE
for each gene loci (purple when r ≥ 0.60). Pink profile represents the frequency values for the Up-Gain category (U-G).
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Table 1 Significant U-G regions with the associated genes.
regions chr cytobands start end Correlation (average r coefficient) U-G Frequency (average %) Number of genes gene symbols
1 7 p22.3,,p22.2,p22.1,... 13912 12407180 0.75 53.13 97 PDGFA,PRKAR1B,HEATR2,...
2 7 p21.2,p21.1 13980952 18581782 0.83 48.34 16 ETV1,DGKB,TMEM195,...
3 7 p21.1 19741898 19786077 0.77 48.44 2 TWISTNB,TMEM196
4 7 p21.1 20735744 20825207 0.81 50.00 2 ABCB5,SP8
5 7 p15.3,p15.2 22277336 26372745 0.85 50.00 28 RAPGEF5,IL6,TOMM7,...
6 7 p15.2 26682190 27829944 0.68 50.00 18 SKAP2,HOXA1,HOXA2,...
7 7 p14.3 29901392 33407268 0.78 50.00 29 WIPF3,SCRN1,FKBP14,...
8 7 p14.3,p14.2 34692740 36658380 0.72 48.44 13 NPSR1,DPY19L1,TBX20,...
9 7 p14.1,p13,p12.3,... 37856706 50759460 0.72 49.60 83 GPR141,TXNDC3,SFRP4,...
10 7 p11.2 54819940 54826939 0.77 * 59.38 1 SEC61G
11 7 p11.2 55086725 55275031 0.77 * 60.94 1 EGFR
12 7 p11.2 55572215 56043680 0.70 59.06 5 VOPP1,SEPT14,ZNF713,...
13 7 p11.2 56125502 56171766 0.70 57.81 4 CCT6A,SUMF2,PHKG1,...
14 7 p11.2,p11.1,q11.21 57269897 66582330 0.66 56.56 25 ERV3,VKORC1L1,GUSB,...
15 7 q11.22,q11.23,q21.11,... 69660980 91851882 0.68 57.74 131 AUTS2,WBSCR17,CALN1,...
16 7 q21.2,q21.3, 92738082 97975672 0.72 56.51 36 SAMD9,SAMD9L,HEPACAM2,...
17 7 q22.1,q22.3,q31.1,... 98456252 141707080 0.71 55.94 343 TMEM130,TRRAP,SMURF1,...
18 7 q34,q35,q36.1,... 141954920 158879258 0.75 56.26 154 TRBV12-2,TRBC1,PRSS1,...
19 20 p13,p12.3,p12.2,... 72762 62897316 0.83 25.62 570 DEFB125,DEFB126,DEFB12,...
Table with the significant Up-regulated and Gained (U-G) regions, indicating: chromosomal bands covered by each region; percentage of samples (%) that are in the U-G category in each region (calculated as
average frequency for all the gene loci in the region); correlation between GE and CN for each region (calculated as average correlation of the gene loci in the region); number of genes located in each region. Total
number of GBM samples analysed: N = 64. Marked with * the correlations calculated between unsegmented GE and segmented CN. Due to size limitations the table only includes a maximum of 3 cytobands or 3
genes. Complete information corresponding to this U-G regions is included as supplementary material: Additional-file-1.
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Table 2 Significant D-L regions with the associated genes.
regions chr cytobands start end Correlation (average r coefficient) U-G Frequency (average %) Number of genes gene symbols
1 10 p14 9365826 11653762 0.62 57.19 5 CUGBP2,C10orf31,USP6NL,...
2 10 p13,p12.33,p12.31,... 16746068 24410224 0.64 59.98 39 RSU1,CUBN,TRDMT1,...
3 10 p12.1,p11.23,p11.22,... 25189544 47921720 0.63 60.50 103 PRTFDC1,ENKUR,THNSL1,...
4 10 p11.2 38238795 38265453 0.60 * 60.94 1 ZNF25
5 10 q11.22,,q11.23 49203737 53404614 0.68 62.91 42 FAM25C,BMS1P7,PTPN20C,...
6 10 q21.1,q21.2,q21.3,... 59989486 82351987 0.65 64.07 152 IPMK,CISD1,UBE2D1,...
7 10 q23.1, 84190870 87742781 0.66 65.63 9 NRG3,GHITM,PCDH21,...
8 10 q23.31,q23.32,q23.33 91498034 97024055 0.62 67.19 39 KIF20B,HTR7,RPP30,...
9 10 q24.1 97391080 97763109 0.62 66.41 6 ALDH18A1,TCTN3,ENTPD1,...
10 10 q24.1,q24.2,q24.31,... 98081203 134474152 0.67 68.70 253 DNTT,OPALIN,TLL2,...
11 13 q12.13,q12.2 27693163 28017254 0.60 28.13 5 USP12,RPL21,RASL11A,...
12 13 q12.2,,q12.3 28367434 30381664 0.61 30.29 13 GSX1,PDX1,ATP5EP2,...
13 13 q13.3,q14.11,q14.12,... 35881808 61059301 0.73 35.48 124 NBEA,MAB21L1,DCLK1,...
14 13 q21.32,q21.33 67340716 70478658 0.62 35.94 2 PCDH9,KLHL1
15 13 q22.2,q22.3,q31.1 76451567 80912598 0.63 37.40 15 KCTD12,IRG1,CLN5,...
16 13 q31.3, 92785210 94467454 0.62 34.38 2 GPC5,GPC6
17 13 q32.1,q32.2,q32.3,... 95812885 106130800 0.64 33.35 38 ABCC4,CLDN10,DZIP1,...
18 13 q33.3 108170700 108931486 0.95 27.73 4 FAM155A,LIG4,ABHD13,...
19 13 q34 110422550 111549152 0.89 23.44 9 IRS2,COL4A1,COL4A2,...
20 14 q11.2,q12,q13.1,... 19686156 70583360 0.75 18.44 389 TTC5,CCNB1IP1,PARP2,...
21 14 q24.2 71478110 72101080 0.74 17.19 2 PCNX,SIPA1L1
22 14 q24.2,,q24.3 73223406 76274521 0.69 17.19 52 DPF3,DCAF4,ZFYVE1,...
23 14 q24.3,,q31.1 77825772 80673424 0.75 17.19 14 TMED8,AHSA1,ISM2,...
24 22 q11.1,q11.21,q11.22,... 16157622 51224902 0.73 24.93 490 POTEH,CESK1,XKR3,...
Table with the significant Down-regulated and Lost (D-L) regions, indicating: chromosomal bands covered by each region; percentage of samples (%) that are in the D-L category in each region (calculated as
average frequency for all the gene loci in the region); correlation between GE and CN for each region (calculated as average correlation of the gene loci in the region); number of genes located in each region. Total
number of GBM samples analysed: N = 64. Marked with * : correlations calculated between unsegmented GE and segmented CN. Due to size limitations the table only includes a maximum of 3 cytobands or 3
genes. Complete information corresponding to this D-L regions is included as supplementary material: Additional-file-2.
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region. By contrast, we found RB1 tumor suppressor in
region 13 of the D-L list; and this gene -included in chr
13- is a clear candidate to drive the alteration of tumor
cells. With respect to EGFR, it has the highest U-G fre-
quency observed (60.9%, Table 1) and therefore the
method reveals this gene locus as the most common GE
up-regulated and CN gained in the GBM samples. The
alteration of EGFR can be associated with other genes that
regulate its function, also found by the method. This is the
case of VOPP1 and RAB11FIP2. VOPP1 is also known as
ECOP (EGFR-coamplified and overexpressed protein) or
GASP (Glioblastoma-amplified secreted protein), and is
found in region 12 of the U-G list (Table 1). RAB11FIP2 is
a suppressor of the endocytic internalization of EGFR and
it is found in region 10 of the D-L list (Table 2) [17]. The
presence of these genes in the hotspots found for GBM
supports the value of the method described. There are
many other interesting genes in the identified altered
genomic regions, that can be useful for further investiga-
tions on the disease studied.
Complete information corresponding to the genes found
in the significant U-G regions and D-L regions is
included respectively as supplementary material in Addi-
tional-file-1 (for the data corresponding to Table 1) and
Additional-file-2 (for the data corresponding to Table 2).
Conclusions
The combined analysis of CN and GE data obtained using
DNA genome and RNA expression microarrays for paired
samples is a very powerful approach to uncover key altered
regions in a biological state studied. We present a robust
method to find genomic regions that show simultaneous
significant changes in both CN and GE. Our calculations
applied to a cancer dataset find expected known genomic
alterations and many others identified as key altered geno-
mic regions. This approach is also proposed as an ade-
quate strategy to identify driver or causal genes under the
hypothesis that disease-associated gene expression changes
are frequently induced by genomic alterations.
Materials and methods
Data
In this study we use a dataset of 64 human samples from
Glioblastoma Multiforme (GBM) [7] that includes for
each sample: Affymetrix DNA microarrays applied to
detect of genome-wide CN changes and Affymetrix RNA
expression microarrays applied to detect of GE changes.
We used the same subgroup of samples that was pre-
viously analysed in Ortiz-Estevez et al. [11].
GE and CN normalization and signals calculation
GE data were processed using RMA algorithm [18]
applied to the human gene expression microarrays:
Affymetrix HGU133 plus 2.0 (using the same strategy
followed in [19,20]). CRMAv2 algorithm [21] was
applied to normalize the raw data and obtain the sig-
nals from the Affymetrix Human Mapping 500K SNP
arrays. The processed signals were divided by the med-
ian of the normal samples for each element (SNP or
gene) and then the log2 was computed. These log2
ratio signals were smoothed and segmented using Cir-
cular Binary Segmentation (CBS) algorithm [22] with
the default parameters implemented in the DNAcopy R
package.
Correlation between GE and CN
Pearson Correlation Coefficients (r) of the segmented GE
and CN data were calculated taking the values of the seg-
mented copy number and gene expression at the central
point of the genomic position for each gene. P-values for
the correlation coefficient of every gene loci were com-
puted and adjusted by Bonferroni method. The established
threshold for the selection of significantly correlated gene
loci was correlation coefficient r ≥ 0.60, which corresponds
to adjusted p-value < 0.005. When using the gene loci GE
unsegmented signal, the same correlation threshold and
p-value cutoff were applied.
Frequency of U-G and D-L alterations
The thresholds that define DNA copy number gains and
losses and up and down gene regulation were established
applying k-Means algorithm, fixing three clusters (k = 3)
on the segmented data, and done independently for the
CN data and for the GE data. The CN data values were
classified into gained (G), lost (L) or no-change (N) and
the GE values were classified as up-regulated (U), down-
regulated (D) or no-change (N). The thresholds found by
k-Means for CN in the GBM dataset were > 0.19 (of the
log2 ratio signals) for gain and < -0.15 for loss. The thresh-
olds found for GE in the GBM were > 0.10 (of the log2
ratio signals) for up-regulation and < -0.12 for down-regu-
lation. A contingency table with the 9 possible categorical
states for the two types of data was built for every gene
locus. A cutoff threshold was set up for the frequency of
up-regulated and gained (U-G) and for the down-regu-
lated and lost (D-L) categories, based on the empirical
cumulative distributions of the categories. Taking into
account the gene loci, the significant altered regions were
defined as the ones that had a frequency ≥ than the upper
10% quantile of the distribution of U-G or the distribution
of D-L.
General workflow for identification of key regions in
the genome
Following the steps described above, we present a gen-
eral workflow (Figure 5) that illustrates the strategy to
achieve a combined paired analysis of datasets from
genome-wide microarrays, both for GE and CN.
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The workflow includes the different steps, the applied
methods and the progression of the analysis. The strategy
designed searches for high correlation between chromo-
somal regions that present a significant CN alteration (as
gain or loss) and regions with significant GE change (as
up or down). In this way, it determines which CN altera-
tions have a strong influence on GE patterns. Key
regions, i.e. hotspots in the genome, are defined as those
regions simultaneously chosen as significantly correlated
and frequently altered in both GE and CN.
Figure 5 Workflow of the method for the analysis of gene expression and copy number changes. The figure illustrates the strategy to
achieve a combined paired analysis of data sets from genome-wide microarrays both for GE and CN. The method searches for high correlation
between segmented chromosomal regions that present a significant CN alteration (gain or loss) and segmented regions with significant GE
change (up or down). The frequency of alteration is also analysed. The selected loci (hotspots) are regions chosen as significantly correlated and
frequently altered in both GE and CN.
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Additional material
Additional file 1: Spreadsheet with the complete data
corresponding to Table 1.
Additional file 2: Spreadsheet with the complete data
corresponding to Table 2.
Additional file 3: Detailed view of all the 22 chromosomes showing
the CN and GE correlation and the U-G or D-L categories frequency
for the GBM dataset. The genomic regions are represented in X-axis.
Blue and purple dots show the correlation coefficients between CN and
GE for each gene loci (purple when r ≥ 0.60). Pink and green profiles
represent the frequency values for the Up-Gain (U-G) category or the
Down-Loss (D-L) category respectively.
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